Star Equity (STRR) 10-Q 7 May 18 2018 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2018	Apr. 24, 2018
Document And Entity Information [Abstract]
Entity Registrant Name	DIGIRAD CORP
Entity Central Index Key	707,388
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Outstanding (in shares)		20,119,118

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenues:
Services	$ 22,623	$ 23,057
Product and product-related	2,842	2,783
Total revenues	25,465	25,840
Cost of revenues:
Services	19,261	18,583
Product and product-related	1,597	1,655
Total cost of revenues	20,858	20,238
Gross profit	4,607	5,602
Operating expenses:
Marketing and sales	1,467	1,783
General and administrative	4,392	4,896
Amortization of intangible assets	357	374
Total operating expenses	6,216	7,053
Loss from operations	(1,609)	(1,451)
Other expense, net
Other expense, net	(17)	0
Interest expense, net	(217)	(193)
Total other expense	(234)	(193)
Loss before income taxes	(1,843)	(1,644)
Income tax benefit (expense)	455	(607)
Net loss from continuing operations	(1,388)	(2,251)
Income from discontinued operations, net of tax	5,494	175
Net income (loss)	$ 4,106	$ (2,076)
Net income (loss) per share - basic and diluted
Continuing operations (in usd per share)	$ (0.07)	$ (0.11)
Discontinued operations (in usd per share)	0.27	0.01
Net income (loss) per share - basic and diluted (in usd per share)	0.20	(0.10)
Dividends declared per common share (in usd per share)	$ 0.055	$ 0.05
Other comprehensive (loss) income:
Unrealized gain on available-for-sale securities	$ 0	$ 38
Reclassification of unrealized gains on available-for-sale securities to retained earnings	(17)	0
Total other comprehensive (loss) income	(17)	38
Comprehensive income (loss)	$ 4,089	$ (2,038)

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 1,033	$ 1,877
Securities available-for-sale	116	97
Accounts receivable, net	12,752	15,887
Inventories, net	5,755	5,501
Restricted cash	243	242
Other current assets	2,287	1,972
Total current assets	22,186	25,576
Property and equipment, net	27,176	28,365
Intangible assets, net	7,473	7,830
Goodwill	2,392	2,392
Restricted cash	101	101
Non-current assets held for sale	0	1,736
Other assets	634	703
Total assets	59,962	66,703
Current liabilities:
Accounts payable	5,712	5,207
Accrued compensation	3,208	5,507
Accrued warranty	182	204
Deferred revenue	1,922	2,302
Current liabilities held for sale	0	835
Other current liabilities	2,666	2,915
Total current liabilities	13,690	16,970
Long-term debt	13,001	19,500
Deferred tax liabilities	361	254
Other liabilities	1,979	2,180
Total liabilities	29,031	38,904
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.0001 par value: 80,000,000 shares authorized; 20,118,336 and 20,060,311 shares issued and outstanding (net of treasury shares) at March 31, 2018 and December 31, 2017, respectively	2	2
Treasury stock, at cost; 2,588,484 shares at March 31, 2018 and December 31, 2017	(5,728)	(5,728)
Additional paid-in capital	147,189	148,163
Accumulated other comprehensive loss	(22)	(5)
Accumulated deficit	(110,510)	(114,633)
Total stockholders’ equity	30,931	27,799
Total liabilities and stockholders’ equity	$ 59,962	$ 66,703

CONDENSED CONSOLIDATED BALANCE4

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Preferred stock, par value (in usd per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized (in shares)	10,000,000	10,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in usd per share)	$ 0.0001	$ 0.0001
Common stock, authorized (in shares)	80,000,000	80,000,000
Common stock, issued (in shares)	20,118,336	20,060,311
Common stock, outstanding (in shares)	20,118,336	20,060,311
Treasury stock (in shares)	2,588,484	2,588,484

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Operating activities
Net income (loss)	$ 4,106	$ (2,076)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	1,910	2,001
Amortization of intangible assets	370	578
Provision for bad debt, net of (recoveries)	13	(10)
Gain on sale of discontinued operations	(6,261)	0
Stock-based compensation	200	263
Amortization and write-off of deferred loan costs	54	82
(Gain) loss on sale of assets	5	(7)
Deferred income taxes	107	723
Other, net	17	0
Changes in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable	3,119	880
Inventories	(177)	45
Other assets	185	336
Accounts payable	21	(322)
Accrued compensation	(2,299)	(42)
Deferred revenue	(568)	188
Other liabilities	(382)	(715)
Net cash provided by operating activities	420	1,924
Investing activities
Purchases of property and equipment	(201)	(492)
Proceeds from sale of discontinued operations	6,844	0
Proceeds from sale of property and equipment	40	7
Purchases of securities available-for-sale	(14)	(17)
Maturities of securities available-for-sale	0	917
Net cash provided by investing activities	6,669	415
Financing activities
Proceeds from long-term borrowings	7,758	1,500
Repayment of long-term debt	(14,257)	(2,840)
Loan issuance costs	(4)	0
Dividends paid	(1,105)	(994)
Taxes paid related to net share settlement of equity awards	(70)	(192)
Repayment of obligations under capital leases	(254)	(196)
Net cash used in financing activities	(7,932)	(2,722)
Net decrease in cash and cash equivalents and restricted cash	(843)	(383)
Cash and cash equivalents and restricted cash at beginning of period	2,220	5,679
Cash and cash equivalents and restricted cash at end of period	1,377	5,296
Non-Cash Investing Activities
Assets acquired by entering into capital leases	$ 16	$ 1,440

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation Basis of Presentation The unaudited condensed consolidated financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed consolidated financial statements are unaudited and do not contain all the information required by U.S. generally accepted accounting principles ("GAAP") to be included in a full set of financial statements. The unaudited condensed consolidated balance sheet at December 31, 2017 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited consolidated financial statements for our fiscal year ended December 31, 2017 , filed with the SEC on Form 10-K on February 28, 2018 , include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations, cash flows, and balance sheets for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year. As discussed in Note 2, the results of our Medical Device Sales and Services ("MDSS") are presented as discontinued operations and, as such, are excluded from both continuing operations and segment results for all periods presented. Use of Estimates Preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported amounts of revenues and expenses. By their nature, estimates are subject to an inherent degree of uncertainty. Actual results could differ from management’s estimates. Recently Adopted Accounting Standards In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires amounts generally described as restricted cash and restricted cash equivalents be included with cash and cash equivalents when reconciling the total beginning and ending amounts for the periods shown on the statement of cash flows. The pronouncement is effective for fiscal years beginning after December 15, 2017, and for interim periods within those periods, using a retrospective transition method to each period presented. We adopted ASU 2016-18 effective January 1, 2018 which resulted in an increase of $0.1 million in net cash flows used in financing activities that was previously reported for three months ended March 31, 2017. In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, which amended the existing accounting standards for the accounting for financial instruments. The amendments require equity investments, with certain exceptions, to be measured at fair value with changes in fair value recognized in net income. The new standard is effective prospectively for fiscal years beginning after December 15, 2017. We adopted ASU 2016-01 on January 1, 2018. As a result of the adoption, we recorded an increase to retained earnings of $17 thousand to recognize the unrealized gains previously recorded within accumulated other comprehensive income. Subsequent changes in the fair value of our marketable securities will be recorded to other expense, net. See Note 7 for further details. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers which supersedes current revenue recognition guidance, including most industry-specific guidance. The guidance provides that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance also requires additional disclosure about the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. We adopted Topic 606 as of January 1, 2018 using the modified retrospective transition method. Under the modified retrospective method, the Company would recognize the cumulative effect of initially applying the standard as an adjustment to opening retained earnings at the date of initial application; however, we did not have any material adjustments as of the date of the adoption. The comparative periods have not been restated and continue to be reported under the accounting standards in effect for those periods. See Note 3 for expanded revenue disclosures and updates to our revenue recognition policy. Recently Issued Accounting Standards In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, which simplifies the subsequent measurement of goodwill by removing the second step of the two-step impairment test. The amendment requires an entity to perform its annual, or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit's fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The amendment should be applied on a prospective basis. The pronouncement is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We are currently evaluating the impact that implementation of this guidance will have on our financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which amended the existing accounting standards for the accounting for leases. The amendments are based on the principle that assets and liabilities arising from leases should be recognized within the financial statements. The Company is required to adopt the amendments beginning in 2019. Early adoption is permitted. The amendments must be applied using a modified retrospective transition approach and the FASB decided not to permit a full retrospective transition approach. We currently expect that most of our operating lease commitments will be subject to the update and recognized as operating lease liabilities and right-of-use assets upon adoption. However, we are currently evaluating the effect that implementation of this update will have upon adoption on our consolidated financial position and results of operations.

Discontinued Operations

Discontinued Operations	3 Months Ended
	Mar. 31, 2018
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Discontinued Operations On February 1, 2018 , the Company completed the sale of its customer contracts relating to our MDSS post-warranty service business to Philips North America LLC ("Philips") pursuant to an Asset Purchase Agreement, dated as of December 22, 2017 for $8.0 million . The total cash proceeds were adjusted for deferred revenue liabilities assigned to Philips at the closing date, as well as $0.5 million of proceeds held in escrow, subject to claims for breaches of general representation and warranties. The escrow amount was recorded in other current assets as of March 31, 2018 . Prior to the contemplation of the transaction entered into above, on September 28, 2017 , we received notification from Philips that our distribution agreement to sell Philips imaging systems on a commission basis would be terminated, effective December 31, 2017. As a result, our product sales activities within our MDSS reportable segment were also discontinued effective in the first quarter of 2018. The Company deemed the disposition of our MDSS reportable segment in the first quarter of 2018 to represent a strategic shift that will have a major effect on our operations and financial results, in accordance with the provisions of FASB authoritative guidance on the presentation of financial statements, we have classified the results of our MDSS segment as discontinued operations in our condensed consolidated statement of operations for all periods presented. Additionally, the related assets and liabilities associated with the discontinued operations were reclassified as held for sale in our condensed consolidated balance sheet. The Company has allocated a portion of interest expense to discontinued operations since the proceeds received from the sale were required to be used to pay down outstanding borrowings under our revolving credit facility with Comerica Bank, a Texas banking association ("Comerica"). The allocation was based on the ratio of proceeds received in the sale to total borrowings for the period. In addition, certain general and administrative costs related to corporate and shared service functions previously allocated to the MDSS reportable segment are not included in discontinued operations. The following table presents financial results of the MDSS business: Three Months Ended March 31, (in thousands) 2018 2017 Total revenues $ 624 $ 3,240 Total cost of revenues 516 1,735 Gross profit 108 1,505 Operating expenses: Marketing and sales 85 617 General and administrative 172 208 Amortization of intangible assets 13 204 Gain on sale of discontinued operations (6,261 ) — Total operating expenses (5,991 ) 1,029 Income from discontinued operations 6,099 476 Interest expense (26 ) (122 ) Income from discontinuing operations before income taxes 6,073 354 Income tax expense (579 ) (179 ) Income from discontinuing operations $ 5,494 $ 175 The following table summarizes the major classes of assets and liabilities of discontinued operations that were included in the Company's balance sheet: (in thousands) March 31, December 31, Carrying amounts of assets included as part of discontinued operations: Intangible assets, net $ — $ 637 Goodwill — 1,099 Total assets classified as held for sale in the condensed consolidated balance sheet $ — $ 1,736 Carrying amounts of liabilities included as part of discontinued operations: Deferred revenue $ — $ 835 Total liabilities classified as held for sale in the condensed consolidated balance sheet $ — $ 835 The following table presents supplemental cash flow information of discontinued operations: Three Months Ended March 31, (in thousands) 2018 2017 Operating activities: Depreciation $ 2 $ 9 Amortization of intangible assets $ 13 $ 204 Gain on sale of discontinued operations $ (6,261 ) $ — Stock-based compensation $ (1 ) $ 8 Investing activities: Proceeds from the sale of discontinued operations $ 6,844 $ — Purchases of property, plant and equipment $ — $ —

Revenue

Revenue	3 Months Ended
	Mar. 31, 2018
Revenue from Contract with Customer [Abstract]
Revenue	Revenue Product and Product-Related Revenues and Services Revenue Product and product-related revenue are generated from the sale of gamma cameras and post-warranty maintenance service contracts within our Diagnostic Imaging reportable segment. Services revenue are generated from providing diagnostic imaging and cardiac monitoring services to customers within our Diagnostic Services and Mobile Healthcare reportable segments. Services revenue also includes lease income generated from interim rentals of imaging systems to our customers. Revenue Recognition Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Taxes collected from customers, which are subsequently remitted to governmental authorities, are excluded from revenue. The majority of our contracts have a single performance obligation as we provide a series of distinct services that are substantially the same and are transferred with the same pattern to the customer. For contracts with multiple performance obligations, we allocate the total transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract. We use an observable price to determine the stand-alone selling price for separate performance obligations or a cost plus margin approach when one is not available. Our products are generally not sold with a right of return and the Company does not provide significant credits or incentives, which may be required for as variable consideration when estimating the amount of revenue to be recognized. Disaggregation of Revenue The following table presents our revenues disaggregated by major source: (in thousands) Diagnostic Services Diagnostic Imaging Mobile Healthcare Total Major Goods/Service Lines Mobile Imaging and Cardiac Monitoring $ 11,898 $ — $ 8,079 $ 19,977 Camera — 1,070 — 1,070 Camera Support — 1,744 — 1,744 Revenue from Contracts with Customers 11,898 2,814 8,079 22,791 Lease Income 127 28 2,519 2,674 Total Revenues $ 12,025 $ 2,842 $ 10,598 $ 25,465 Timing of Revenue Recognition Services and goods transferred over time $ 10,964 $ 1,720 $ 10,491 $ 23,175 Services and goods transferred at a point in time 1,061 1,122 107 2,290 Total Revenues $ 12,025 $ 2,842 $ 10,598 $ 25,465 Nature of Goods and Services Mobile Imaging and Cardiac Monitoring Within our Diagnostic Services and Mobile Healthcare reportable segments, our sales are derived from providing services and materials to our customers, primarily physician practices and hospitals, that allow them to perform diagnostic imaging services at their site. We typically bundle our services in providing staffing, our imaging systems, licensing, radiopharmaceuticals, and supplies depending on our customers' needs. Our contracts with customers are typically entered into annually and are billed on a fixed rate per-day or per-scan basis, depending on terms of the contract. For the majority of these contracts, the Company has the right to invoice the customer in an amount that directly corresponds with the value to the customer of the Company's performance to date. The Company uses the practical expedient to recognize revenue corresponding with amounts we have the right to invoice for services performed. Diagnostic Services also offers remote cardiac event monitoring services. These services include provision of a monitor, remote monitoring by registered nurses, and 24 hours a day, 7 days a week monitoring support for our patients and physician customers. We provide our services under contracts with our customers that typically allow for direct billing to Medicare, Medicaid, or third-party private payors once the monitoring cycle is complete. Typically, our contracts can be canceled at any time, and are generally used to define billing responsibilities amongst the parties. Our cardiac event monitoring services are provided primarily through an independent diagnostic testing facility model which allows us to bill Medicare, Medicaid, or a third-party healthcare insurer directly for services provided. We also receive reimbursement directly from patients through co-pays and self-pay arrangements. Billings for services reimbursed by third party payors, including Medicare, are recorded as revenue net of contractual allowances. Contractual allowances are estimated based on historical collections by Current Procedural Terminology (CPT) code for specific payors, or class of payors. Adjustments to the estimated receipts, based on final settlement with the third-party payors, are recorded upon settlement. Camera Within our Diagnostic Imaging segment, camera revenues are generated from the sale of internally developed solid-state gamma camera imaging systems. We recognize revenue upon transfer of control to the customer, which is generally upon delivery and acceptance. We also provide installation services and training on cameras we sell, primarily in the United States. Installation and initial training is generally performed shortly after delivery. The Company recognizes revenues for installation and training over time as the customer receives and consumes benefits provided as the Company performs the installation services. Our sale of imaging systems includes a one -year warranty which we account for as an assurance-type warranty. The expected costs associated with our standard warranties and field service actions continue to be recognized as expense when cameras are sold. Maintenance service contracts sold beyond the term of our standard warranties are accounted for as a service-type warranty and revenue is deferred and recognized ratably over the period of the obligation. Camera Support Within our Diagnostic Imaging segment, camera support revenue is derived from the sale of separately-priced extended maintenance contracts to camera owners, training, and paid service arrangements when a customer does not have an extended warranty and parts that are sold by the service department. Our separately priced service contracts range from 12 to 48 months. Service contracts are usually billed at the beginning of the contract period or at periodic intervals (e.g. monthly or quarterly) and revenue is recognized ratably over the term of the agreement. Services and training revenues are recognized in the period the services and training are performed. Revenue for sales of parts are recognized when the parts are delivered to the customer and control is transferred. Lease Income Within primarily our Mobile Healthcare segment, we also generate income from interim rentals of our imaging systems to customers that are in the midst of new construction or refurbishing their current facilities. Rental contracts are structured as either a weekly or monthly payment arrangement and are accounted for as operating leases. Revenues are recognized on a straight-line basis over the term of the rental. Deferred Revenues We record deferred revenues when cash payments are received or due in advance of our performance, including amounts which are refundable. We have determined our contracts do not include a significant financing component. The majority of our deferred revenue relates to payments received on camera support post-warranty service contracts which are billed at the beginning of the annual contract period or at periodic intervals (e.g. monthly or quarterly). At December 31, 2017, the Company deferred revenues balance was $2.4 million , of which $0.9 million of this was recognized as revenue during the first quarter. As of March 31, 2018 , deferred revenue was $2.0 million . The decrease of $0.4 million was mainly due to the timing of when customer payments are received in relation to the service contract period. The Company has elected to use the practical expedient under ASC 606 to exclude disclosures of unsatisfied remaining performance obligations for (i) contracts having an original expected length of one year or less or (ii) contracts which the practical expedient has been applied to recognize revenue at the amount to which it has a right to invoice. Contract Costs We recognize an asset for the incremental costs of obtaining a contract with a customer if we expect the benefit of those costs to be longer than one year. The Company applies a practical expedient to expense costs as incurred for costs to obtain a contract when the amortization period would have been one year or less. These costs mainly include the Company's internal sales commissions; under the terms of these programs these are generally earned and the costs are recognized at the time the revenue is recognized.

Basic and Diluted Net Income (L

Basic and Diluted Net Income (Loss) Per Share	3 Months Ended
	Mar. 31, 2018
Earnings Per Share, Basic and Diluted [Abstract]
Basic and Diluted Net Income (Loss) Per Share	Basic and Diluted Net Income (Loss) Per Share For the three months ended March 31, 2018 and 2017 , basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares and vested restricted stock units outstanding during the period. Diluted net income per common share is calculated to give effect to all dilutive securities, if applicable, using the treasury stock method. In periods for which there is a net loss, diluted loss per common share is equal to basic loss per common share, since the effect of including any common stock equivalents would be antidilutive. The following table sets forth the reconciliation of shares used to compute basic and diluted net income (loss) per share for the periods indicated: Three Months Ended March 31, (shares in thousands) 2018 2017 Numerator: Loss from continuing operations $ (1,388 ) $ (2,251 ) Income from discontinued operations 5,494 175 Net income (loss) $ 4,106 $ (2,076 ) Denominator: Weighted average shares outstanding - basic 20,092 19,933 Dilutive potential common stock outstanding: Stock options — — Restricted stock units — — Weighted average shares outstanding - diluted 20,092 19,933 Income (loss) per common share - basic Continuing operations $ (0.07 ) $ (0.11 ) Discontinued operations $ 0.27 $ 0.01 Net income (loss) per common share - basic $ 0.20 $ (0.10 ) Income (loss) per common share - diluted Continuing operations $ (0.07 ) $ (0.11 ) Discontinued operations $ 0.27 $ 0.01 Net income (loss) per common share - diluted $ 0.20 $ (0.10 ) The following weighted average outstanding common stock equivalents were not included in the calculation of diluted net income per share because their effect was anti-dilutive: Three Months Ended March 31, (shares in thousands) 2018 2017 Stock options 207 315 Restricted stock units 129 69 Total 336 384

Inventories

Inventories	3 Months Ended
	Mar. 31, 2018
Inventory Disclosure [Abstract]
Inventories	Inventories The components of inventories are as follows: (in thousands) March 31, December 31, Inventories: Raw materials $ 2,486 $ 2,331 Work-in-process 1,781 2,094 Finished goods 1,933 1,529 Total inventories 6,200 5,954 Less reserve for excess and obsolete inventories (445 ) (453 ) Total inventories, net $ 5,755 $ 5,501

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2018
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment consists of the following: (in thousands) March 31, December 31, 2017 Property and equipment: Land $ 1,170 $ 1,170 Buildings and leasehold improvements 2,946 2,946 Machinery and equipment 55,735 55,152 Computer hardware and software 4,633 4,615 Total property and equipment 64,484 63,883 Less accumulated depreciation (37,308 ) (35,518 ) Total property and equipment, net $ 27,176 $ 28,365

Financial Instruments

Financial Instruments	3 Months Ended
	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Financial Instruments	Financial Instruments Assets and Liabilities Measured at Fair Value on a Recurring Basis. The following table presents information about our financial assets that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilize to determine such fair value at March 31, 2018 and December 31, 2017 . Fair Value as of March 31, 2018 (in thousands) Level 1 Level 2 Level 3 Total Assets: Equity securities $ 116 $ 88 $ — $ 204 Total $ 116 $ 88 $ — $ 204 Fair Value as of December 31, 2017 (in thousands) Level 1 Level 2 Level 3 Total Assets: Equity securities $ 97 $ 111 $ — $ 208 Total $ 97 $ 111 $ — $ 208 We did not reclassify any investments between levels in the fair value hierarchy during the three months ended March 31, 2018 . The investment in equity securities consists of common stock of publicly traded companies. The fair value of these securities is based on the closing prices observed on March 31, 2018 . Securities Available-for-Sale As of March 31, 2018 , securities available-for-sale consist of investments in equity securities that are publicly traded. These investments include shares held in Birner Dental Management Services ("Birner Dental"), a publicly traded company whose board of directors include a current Director of the Company. We classify a portion of equity securities as available-for-sale and as current assets, as the sale of such securities may be required prior to maturity to execute management strategies. One of our equity securities, Perma-Fix Medical S.A. ("Perma-Fix Medical"), is classified as an other asset (non-current), as the investment is strategic in nature and our current intent is to hold the investment over a several year period. Securities available-for-sale are carried at fair value, with the unrealized gains and losses presented within 'other expense, net' on our condensed consolidated statement of operations. As of December 31, 2017, the accumulated unrealized gains on these investments was $17 thousand , which was reclassified from accumulated other comprehensive income into beginning retained earnings upon adoption of ASU 2016-01. The following table sets forth the composition of securities available-for-sale as of March 31, 2018 and December 31, 2017 (in thousands). Cost Unrealized Fair Value As of March 31, 2018 Gains Losses Equity securities $ 221 $ — $ (17 ) $ 204 $ 221 $ — $ (17 ) $ 204 Cost Unrealized Fair Value As of December 31, 2017 Gains Losses Equity securities $ 191 $ 17 $ — $ 208 $ 191 $ 17 $ — $ 208

Debt

Debt	3 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
Debt	Debt A summary of long-term debt is as follows: March 31, 2018 December 31, 2017 (in thousands) Amount Weighted-Average Interest Rate Amount Weighted-Average Interest Rate Long-term debt: Revolving Credit Facility $ 13,001 4.25% $ 19,500 3.90% Total borrowings $ 13,001 $ 19,500 On June 21, 2017, the Company entered into a Revolving Credit Agreement (the “Comerica Credit Agreement”) with Comerica. The Comerica Credit Agreement provides for a five -year revolving credit facility with a maximum credit amount of $25.0 million maturing in June 2022, upon which a balloon payment on the balance is due. Under the Comerica Credit Facility, the Company can request the issuance of letters of credit in an aggregate amount not to exceed $1.0 million at any one time. In connection with the sale of our post-warranty service customer contracts to Philips, the Company entered into an Amendment No. 1 to the Comerica Credit Agreement, dated January 30, 2018 (the "Amendment"). The Amendment to the Comerica Credit Agreement reduced the revolving credit commitment from $25.0 million to $20.0 million . As of March 31, 2018 , our borrowing availability under the Comerica Credit Agreement was $6.9 million . In connection with the Amendment, during the three months ended March 31, 2018 , approximately $0.1 million of unamortized loan fees were written off in proportion to the decrease in our borrowing capacity. As of March 31, 2018 , the unamortized loan fees were $0.2 million , which are being amortized on a straight-line basis to interest expense over the five -year term. At the Company’s option, the Comerica Credit Facility will bear interest at either (i) the LIBOR Rate, as defined in the Comerica Credit Agreement, plus a margin of 2.35% ; or (ii) the PRR-based Rate, plus a margin of 0.5% . As further defined in the Comerica Credit Agreement, the "PRR-based Rate" means the greatest of (a) the Prime Rate in effect on such day (as defined in the Comerica Credit Agreement) plus 0.5% , or (b) the daily adjusting LIBOR Rate plus 2.50% . In addition to interest on outstanding borrowings under the Comerica Credit Facility, the revolving credit note bears an unused line fee of 0.25% , which is presented as interest expense. As of March 31, 2018 , we had outstanding borrowings under the Comerica Credit Agreement of $13.0 million at a weighted average interest rate of 4.25% . The Comerica Credit Agreement contains certain representations, warranties, events of default, as well as certain affirmative and negative covenants customary for credit agreements of this type. These covenants include restrictions on borrowings, investments and divestitures, as well as limitations on the Company’s ability to make certain restricted payments. The Comerica Credit Agreement requires us to comply with certain financial covenants, including a Fixed Charge Coverage Ratio and a Funded Debt to Adjusted EBITDA Ratio (each as defined in the Comerica Credit Agreement). The Fixed Charge Coverage Ratio is calculated based on the ratio of (a) Adjusted EBITDA, less (i) cash income taxes paid for such period, less (ii), FCCR Capital Expenditures (as defined in the Comerica Credit Agreement) made during such period, less (iii) payments, repurchases or redemptions of stock made during such period, less (iv) Distributions and Purchases (each as defined in the Comerica Credit Agreement) made during such period, to (b) (i) the Current Maturities of Long Term Debt (each as defined in the Comerica Credit Agreement) as of the last day of such period plus (ii) interest paid during such period. The Fixed Charge Coverage ratio is measured on a quarterly basis as of the most recent fiscal quarter end. Under the Comerica Credit Agreement, we must maintain a fixed charge ratio of at least 1.25 to 1.00 for each trailing twelve-month period as of the end of each fiscal quarter. The funded debt to Adjusted EBITDA ratio (as defined in the Comerica Credit Agreement) must be not more than 2.25 to 1.00 measured at each fiscal quarter. Upon the occurrence and during the continuation of an event of default under the Comerica Credit Agreement, Comerica may, among other things, declare the loans and all other obligations under the Comerica Credit Agreement immediately due and payable and increase the interest rate at which loans and obligations under the Comerica Credit Agreement bear interest. Pursuant to a separate Security Agreement dated June 21, 2017, between the Company, its subsidiaries and Comerica Bank, the Comerica Credit Facility is secured by a first-priority security interest in substantially all of the assets (excluding real estate) of the Company and its subsidiaries and a pledge of all shares and membership interests of the Company’s subsidiaries. At March 31, 2018 , the Company was in compliance with all covenants.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Other Matters In addition to commitments and obligations in the ordinary course of business, we have been, and will likely continue to be, subject to litigation or administrative proceedings incidental to our business, such as claims related to customer disputes, employment practices, wage and hour disputes, product liability, professional liability, commercial disputes, licensure restrictions or denials, and warranty or patent infringement. Responding to litigation or administrative proceedings, regardless of whether they have merit, can be expensive and disruptive to normal business operations. We are not able to predict the timing or outcome of these matters.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes We provide for income taxes under the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of differences between the tax basis of assets or liabilities and their carrying amounts in the financial statements. We provide a valuation allowance for deferred tax assets if it is more likely than not that these items will expire before we are able to realize their benefit. We calculate the valuation allowance in accordance with the authoritative guidance relating to income taxes, which requires an assessment of both positive and negative evidence regarding the realizability of these deferred tax assets, when measuring the need for a valuation allowance. Significant judgment is required in determining any valuation allowance against deferred tax assets. As of December 31, 2017, as a result of a three-year cumulative loss and recent events, such as the unanticipated termination of the Philips distribution agreement and its effect on our near term forecasted income, we concluded that a full valuation allowance was necessary to offset our deferred tax assets. We intend to maintain a valuation allowance until sufficient positive evidence exists to support its reversal. Intraperiod tax allocation rules require us to allocate our provision for income taxes between continuing operations and other categories of comprehensive income, such as discontinued operations. In periods in which we have a year-to-date pre-tax loss from continuing operations and pre-tax income in other categories of comprehensive income, such as discontinued operations, we must consider that income in determining the amount of tax benefit that results from a loss in continuing operations and that shall be allocated to continuing operations. For the three months ended March 31, 2018 , we recorded income of $5.5 million , net of tax, in discontinued operations related to our MDSS reportable segment and a loss of $1.4 million , net of tax, in continuing operations. As a result of the intraperiod tax allocation rules, for the three months ended March 31, 2018 , the Company recorded an income tax benefit of $0.5 million within continuing operations and $0.6 million of income tax expense within discontinued operations. For the three months ended March 31, 2017, the Company recorded an income tax expense of $0.6 million and $0.2 million within continuing operations and discontinued operations, respectively. For the three months ended March 31, 2018 , the Company expects to utilize $1.1 million of net operating losses associated with projected taxable income in discontinued operations mainly attributable to the gain on the sale of our MDSS post-warranty service contract business. The utilization of net operating losses in 2018 results in a reduction in our deferred tax asset balance, with a corresponding reduction in our valuation allowance, due to our full valuation allowance position discussed above. As of March 31, 2018 , we had unrecognized tax benefits of approximately $3.9 million related to uncertain tax positions. Included in the unrecognized tax benefits were $3.5 million of tax benefits that, if recognized, would reduce our annual effective tax rate, subject to the valuation allowance. We file income tax returns in the US and in various state jurisdictions with varying statutes of limitations. We are no longer subject to income tax examination by tax authorities for years prior to 2013; however, our net operating loss and research credit carryovers arising prior to that year are subject to adjustment. It is our policy to recognize interest expense and penalties related to uncertain income tax matters as a component of income tax expense.

Segments

Segments	3 Months Ended
	Mar. 31, 2018
Segment Reporting [Abstract]
Segments	Segments Our reporting segments have been determined based on the nature of the products and/or services offered to customers or the nature of their function in the organization. We evaluate performance based on the gross profit and operating income (loss). The Company does not identify or allocate its assets by operating segments. During the first quarter of 2018, we have classified the results of our MDSS segment as discontinued operations in our condensed consolidated statement of operations for all periods presented. Accordingly, segment results have been recast for all periods presented to reflect MDSS as discontinued operations. As costs of shared service functions previously allocated to MDSS are not allocable to discontinued operations, prior period corporate costs have been reallocated amongst the continuing reportable segments. Segment information is as follows: Three Months Ended March 31, (in thousands) 2018 2017 Revenue by segment: Diagnostic Services $ 12,025 $ 12,202 Diagnostic Imaging 2,842 2,783 Mobile Healthcare 10,598 10,855 Condensed consolidated revenue $ 25,465 $ 25,840 Gross profit by segment: Diagnostic Services $ 2,247 $ 2,836 Diagnostic Imaging 1,245 1,128 Mobile Healthcare 1,115 1,638 Condensed consolidated gross profit $ 4,607 $ 5,602 Income (loss) from continuing operations by segment: Diagnostic Services $ (290 ) $ 16 Diagnostic Imaging (204 ) (437 ) Mobile Healthcare (1,115 ) (1,030 ) Condensed consolidated loss from continuing operations $ (1,609 ) $ (1,451 )

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On May 1, 2018, the Company announced a cash dividend of $0.055 per share payable on May 30, 2018, to shareholders of record on May 15, 2018.

Basis of Presentation Basis of

Basis of Presentation Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The unaudited condensed consolidated financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed consolidated financial statements are unaudited and do not contain all the information required by U.S. generally accepted accounting principles ("GAAP") to be included in a full set of financial statements. The unaudited condensed consolidated balance sheet at December 31, 2017 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited consolidated financial statements for our fiscal year ended December 31, 2017 , filed with the SEC on Form 10-K on February 28, 2018 , include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations, cash flows, and balance sheets for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year. As discussed in Note 2, the results of our Medical Device Sales and Services ("MDSS") are presented as discontinued operations and, as such, are excluded from both continuing operations and segment results for all periods presented.
Use of Estimates	Use of Estimates Preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported amounts of revenues and expenses. By their nature, estimates are subject to an inherent degree of uncertainty. Actual results could differ from management’s estimates.
Recently Adopted and Recently Issued Accounting Standards	Recently Adopted Accounting Standards In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires amounts generally described as restricted cash and restricted cash equivalents be included with cash and cash equivalents when reconciling the total beginning and ending amounts for the periods shown on the statement of cash flows. The pronouncement is effective for fiscal years beginning after December 15, 2017, and for interim periods within those periods, using a retrospective transition method to each period presented. We adopted ASU 2016-18 effective January 1, 2018 which resulted in an increase of $0.1 million in net cash flows used in financing activities that was previously reported for three months ended March 31, 2017. In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, which amended the existing accounting standards for the accounting for financial instruments. The amendments require equity investments, with certain exceptions, to be measured at fair value with changes in fair value recognized in net income. The new standard is effective prospectively for fiscal years beginning after December 15, 2017. We adopted ASU 2016-01 on January 1, 2018. As a result of the adoption, we recorded an increase to retained earnings of $17 thousand to recognize the unrealized gains previously recorded within accumulated other comprehensive income. Subsequent changes in the fair value of our marketable securities will be recorded to other expense, net. See Note 7 for further details. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers which supersedes current revenue recognition guidance, including most industry-specific guidance. The guidance provides that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance also requires additional disclosure about the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. We adopted Topic 606 as of January 1, 2018 using the modified retrospective transition method. Under the modified retrospective method, the Company would recognize the cumulative effect of initially applying the standard as an adjustment to opening retained earnings at the date of initial application; however, we did not have any material adjustments as of the date of the adoption. The comparative periods have not been restated and continue to be reported under the accounting standards in effect for those periods. See Note 3 for expanded revenue disclosures and updates to our revenue recognition policy. Recently Issued Accounting Standards In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, which simplifies the subsequent measurement of goodwill by removing the second step of the two-step impairment test. The amendment requires an entity to perform its annual, or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit's fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The amendment should be applied on a prospective basis. The pronouncement is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We are currently evaluating the impact that implementation of this guidance will have on our financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which amended the existing accounting standards for the accounting for leases. The amendments are based on the principle that assets and liabilities arising from leases should be recognized within the financial statements. The Company is required to adopt the amendments beginning in 2019. Early adoption is permitted. The amendments must be applied using a modified retrospective transition approach and the FASB decided not to permit a full retrospective transition approach. We currently expect that most of our operating lease commitments will be subject to the update and recognized as operating lease liabilities and right-of-use assets upon adoption. However, we are currently evaluating the effect that implementation of this update will have upon adoption on our consolidated financial position and results of operations.
Revenue	Nature of Goods and Services Mobile Imaging and Cardiac Monitoring Within our Diagnostic Services and Mobile Healthcare reportable segments, our sales are derived from providing services and materials to our customers, primarily physician practices and hospitals, that allow them to perform diagnostic imaging services at their site. We typically bundle our services in providing staffing, our imaging systems, licensing, radiopharmaceuticals, and supplies depending on our customers' needs. Our contracts with customers are typically entered into annually and are billed on a fixed rate per-day or per-scan basis, depending on terms of the contract. For the majority of these contracts, the Company has the right to invoice the customer in an amount that directly corresponds with the value to the customer of the Company's performance to date. The Company uses the practical expedient to recognize revenue corresponding with amounts we have the right to invoice for services performed. Diagnostic Services also offers remote cardiac event monitoring services. These services include provision of a monitor, remote monitoring by registered nurses, and 24 hours a day, 7 days a week monitoring support for our patients and physician customers. We provide our services under contracts with our customers that typically allow for direct billing to Medicare, Medicaid, or third-party private payors once the monitoring cycle is complete. Typically, our contracts can be canceled at any time, and are generally used to define billing responsibilities amongst the parties. Our cardiac event monitoring services are provided primarily through an independent diagnostic testing facility model which allows us to bill Medicare, Medicaid, or a third-party healthcare insurer directly for services provided. We also receive reimbursement directly from patients through co-pays and self-pay arrangements. Billings for services reimbursed by third party payors, including Medicare, are recorded as revenue net of contractual allowances. Contractual allowances are estimated based on historical collections by Current Procedural Terminology (CPT) code for specific payors, or class of payors. Adjustments to the estimated receipts, based on final settlement with the third-party payors, are recorded upon settlement. Camera Within our Diagnostic Imaging segment, camera revenues are generated from the sale of internally developed solid-state gamma camera imaging systems. We recognize revenue upon transfer of control to the customer, which is generally upon delivery and acceptance. We also provide installation services and training on cameras we sell, primarily in the United States. Installation and initial training is generally performed shortly after delivery. The Company recognizes revenues for installation and training over time as the customer receives and consumes benefits provided as the Company performs the installation services. Our sale of imaging systems includes a one -year warranty which we account for as an assurance-type warranty. The expected costs associated with our standard warranties and field service actions continue to be recognized as expense when cameras are sold. Maintenance service contracts sold beyond the term of our standard warranties are accounted for as a service-type warranty and revenue is deferred and recognized ratably over the period of the obligation. Camera Support Within our Diagnostic Imaging segment, camera support revenue is derived from the sale of separately-priced extended maintenance contracts to camera owners, training, and paid service arrangements when a customer does not have an extended warranty and parts that are sold by the service department. Our separately priced service contracts range from 12 to 48 months. Service contracts are usually billed at the beginning of the contract period or at periodic intervals (e.g. monthly or quarterly) and revenue is recognized ratably over the term of the agreement. Services and training revenues are recognized in the period the services and training are performed. Revenue for sales of parts are recognized when the parts are delivered to the customer and control is transferred. Lease Income Within primarily our Mobile Healthcare segment, we also generate income from interim rentals of our imaging systems to customers that are in the midst of new construction or refurbishing their current facilities. Rental contracts are structured as either a weekly or monthly payment arrangement and are accounted for as operating leases. Revenues are recognized on a straight-line basis over the term of the rental. Deferred Revenues We record deferred revenues when cash payments are received or due in advance of our performance, including amounts which are refundable. We have determined our contracts do not include a significant financing component. The majority of our deferred revenue relates to payments received on camera support post-warranty service contracts which are billed at the beginning of the annual contract period or at periodic intervals (e.g. monthly or quarterly). At December 31, 2017, the Company deferred revenues balance was $2.4 million , of which $0.9 million of this was recognized as revenue during the first quarter. As of March 31, 2018 , deferred revenue was $2.0 million . The decrease of $0.4 million was mainly due to the timing of when customer payments are received in relation to the service contract period. The Company has elected to use the practical expedient under ASC 606 to exclude disclosures of unsatisfied remaining performance obligations for (i) contracts having an original expected length of one year or less or (ii) contracts which the practical expedient has been applied to recognize revenue at the amount to which it has a right to invoice. Contract Costs We recognize an asset for the incremental costs of obtaining a contract with a customer if we expect the benefit of those costs to be longer than one year. The Company applies a practical expedient to expense costs as incurred for costs to obtain a contract when the amortization period would have been one year or less. These costs mainly include the Company's internal sales commissions; under the terms of these programs these are generally earned and the costs are recognized at the time the revenue is recognized. Product and Product-Related Revenues and Services Revenue Product and product-related revenue are generated from the sale of gamma cameras and post-warranty maintenance service contracts within our Diagnostic Imaging reportable segment. Services revenue are generated from providing diagnostic imaging and cardiac monitoring services to customers within our Diagnostic Services and Mobile Healthcare reportable segments. Services revenue also includes lease income generated from interim rentals of imaging systems to our customers. Revenue Recognition Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Taxes collected from customers, which are subsequently remitted to governmental authorities, are excluded from revenue. The majority of our contracts have a single performance obligation as we provide a series of distinct services that are substantially the same and are transferred with the same pattern to the customer. For contracts with multiple performance obligations, we allocate the total transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract. We use an observable price to determine the stand-alone selling price for separate performance obligations or a cost plus margin approach when one is not available. Our products are generally not sold with a right of return and the Company does not provide significant credits or incentives, which may be required for as variable consideration when estimating the amount of revenue to be recognized.
Securities Available-for-sale	Securities Available-for-Sale As of March 31, 2018 , securities available-for-sale consist of investments in equity securities that are publicly traded. These investments include shares held in Birner Dental Management Services ("Birner Dental"), a publicly traded company whose board of directors include a current Director of the Company. We classify a portion of equity securities as available-for-sale and as current assets, as the sale of such securities may be required prior to maturity to execute management strategies. One of our equity securities, Perma-Fix Medical S.A. ("Perma-Fix Medical"), is classified as an other asset (non-current), as the investment is strategic in nature and our current intent is to hold the investment over a several year period. Securities available-for-sale are carried at fair value, with the unrealized gains and losses presented within 'other expense, net' on our condensed consolidated statement of operations. As of December 31, 2017, the accumulated unrealized gains on these investments was $17 thousand , which was reclassified from accumulated other comprehensive income into beginning retained earnings upon adoption of ASU 2016-01.

Discontinued Operations (Tables

Discontinued Operations (Tables)	3 Months Ended
	Mar. 31, 2018
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations Information	The following table presents financial results of the MDSS business: Three Months Ended March 31, (in thousands) 2018 2017 Total revenues $ 624 $ 3,240 Total cost of revenues 516 1,735 Gross profit 108 1,505 Operating expenses: Marketing and sales 85 617 General and administrative 172 208 Amortization of intangible assets 13 204 Gain on sale of discontinued operations (6,261 ) — Total operating expenses (5,991 ) 1,029 Income from discontinued operations 6,099 476 Interest expense (26 ) (122 ) Income from discontinuing operations before income taxes 6,073 354 Income tax expense (579 ) (179 ) Income from discontinuing operations $ 5,494 $ 175 The following table summarizes the major classes of assets and liabilities of discontinued operations that were included in the Company's balance sheet: (in thousands) March 31, December 31, Carrying amounts of assets included as part of discontinued operations: Intangible assets, net $ — $ 637 Goodwill — 1,099 Total assets classified as held for sale in the condensed consolidated balance sheet $ — $ 1,736 Carrying amounts of liabilities included as part of discontinued operations: Deferred revenue $ — $ 835 Total liabilities classified as held for sale in the condensed consolidated balance sheet $ — $ 835 The following table presents supplemental cash flow information of discontinued operations: Three Months Ended March 31, (in thousands) 2018 2017 Operating activities: Depreciation $ 2 $ 9 Amortization of intangible assets $ 13 $ 204 Gain on sale of discontinued operations $ (6,261 ) $ — Stock-based compensation $ (1 ) $ 8 Investing activities: Proceeds from the sale of discontinued operations $ 6,844 $ — Purchases of property, plant and equipment $ — $ —

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Mar. 31, 2018
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following table presents our revenues disaggregated by major source: (in thousands) Diagnostic Services Diagnostic Imaging Mobile Healthcare Total Major Goods/Service Lines Mobile Imaging and Cardiac Monitoring $ 11,898 $ — $ 8,079 $ 19,977 Camera — 1,070 — 1,070 Camera Support — 1,744 — 1,744 Revenue from Contracts with Customers 11,898 2,814 8,079 22,791 Lease Income 127 28 2,519 2,674 Total Revenues $ 12,025 $ 2,842 $ 10,598 $ 25,465 Timing of Revenue Recognition Services and goods transferred over time $ 10,964 $ 1,720 $ 10,491 $ 23,175 Services and goods transferred at a point in time 1,061 1,122 107 2,290 Total Revenues $ 12,025 $ 2,842 $ 10,598 $ 25,465

Basic and Diluted Net Income 21

Basic and Diluted Net Income (Loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2018
Earnings Per Share, Basic and Diluted [Abstract]
Reconciliation of Shares Used to Compute Basic and Diluted Net Income (Loss) Per Share	The following table sets forth the reconciliation of shares used to compute basic and diluted net income (loss) per share for the periods indicated: Three Months Ended March 31, (shares in thousands) 2018 2017 Numerator: Loss from continuing operations $ (1,388 ) $ (2,251 ) Income from discontinued operations 5,494 175 Net income (loss) $ 4,106 $ (2,076 ) Denominator: Weighted average shares outstanding - basic 20,092 19,933 Dilutive potential common stock outstanding: Stock options — — Restricted stock units — — Weighted average shares outstanding - diluted 20,092 19,933 Income (loss) per common share - basic Continuing operations $ (0.07 ) $ (0.11 ) Discontinued operations $ 0.27 $ 0.01 Net income (loss) per common share - basic $ 0.20 $ (0.10 ) Income (loss) per common share - diluted Continuing operations $ (0.07 ) $ (0.11 ) Discontinued operations $ 0.27 $ 0.01 Net income (loss) per common share - diluted $ 0.20 $ (0.10 )
Schedule of Antidilutive Securities Excluded from Computation of Net Income (Loss) Per Share	The following weighted average outstanding common stock equivalents were not included in the calculation of diluted net income per share because their effect was anti-dilutive: Three Months Ended March 31, (shares in thousands) 2018 2017 Stock options 207 315 Restricted stock units 129 69 Total 336 384

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2018
Inventory Disclosure [Abstract]
Schedule of Inventory	The components of inventories are as follows: (in thousands) March 31, December 31, Inventories: Raw materials $ 2,486 $ 2,331 Work-in-process 1,781 2,094 Finished goods 1,933 1,529 Total inventories 6,200 5,954 Less reserve for excess and obsolete inventories (445 ) (453 ) Total inventories, net $ 5,755 $ 5,501

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2018
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and equipment consists of the following: (in thousands) March 31, December 31, 2017 Property and equipment: Land $ 1,170 $ 1,170 Buildings and leasehold improvements 2,946 2,946 Machinery and equipment 55,735 55,152 Computer hardware and software 4,633 4,615 Total property and equipment 64,484 63,883 Less accumulated depreciation (37,308 ) (35,518 ) Total property and equipment, net $ 27,176 $ 28,365

Financial Instruments (Tables)

Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Financial Assets Measured at Fair Value on a Recurring Basis	The following table presents information about our financial assets that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilize to determine such fair value at March 31, 2018 and December 31, 2017 . Fair Value as of March 31, 2018 (in thousands) Level 1 Level 2 Level 3 Total Assets: Equity securities $ 116 $ 88 $ — $ 204 Total $ 116 $ 88 $ — $ 204 Fair Value as of December 31, 2017 (in thousands) Level 1 Level 2 Level 3 Total Assets: Equity securities $ 97 $ 111 $ — $ 208 Total $ 97 $ 111 $ — $ 208
Available-for-sale Securities	The following table sets forth the composition of securities available-for-sale as of March 31, 2018 and December 31, 2017 (in thousands). Cost Unrealized Fair Value As of March 31, 2018 Gains Losses Equity securities $ 221 $ — $ (17 ) $ 204 $ 221 $ — $ (17 ) $ 204 Cost Unrealized Fair Value As of December 31, 2017 Gains Losses Equity securities $ 191 $ 17 $ — $ 208 $ 191 $ 17 $ — $ 208

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
Summary of Long-Term Debt	A summary of long-term debt is as follows: March 31, 2018 December 31, 2017 (in thousands) Amount Weighted-Average Interest Rate Amount Weighted-Average Interest Rate Long-term debt: Revolving Credit Facility $ 13,001 4.25% $ 19,500 3.90% Total borrowings $ 13,001 $ 19,500

Segments (Tables)

Segments (Tables)	3 Months Ended
	Mar. 31, 2018
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	Segment information is as follows: Three Months Ended March 31, (in thousands) 2018 2017 Revenue by segment: Diagnostic Services $ 12,025 $ 12,202 Diagnostic Imaging 2,842 2,783 Mobile Healthcare 10,598 10,855 Condensed consolidated revenue $ 25,465 $ 25,840 Gross profit by segment: Diagnostic Services $ 2,247 $ 2,836 Diagnostic Imaging 1,245 1,128 Mobile Healthcare 1,115 1,638 Condensed consolidated gross profit $ 4,607 $ 5,602 Income (loss) from continuing operations by segment: Diagnostic Services $ (290 ) $ 16 Diagnostic Imaging (204 ) (437 ) Mobile Healthcare (1,115 ) (1,030 ) Condensed consolidated loss from continuing operations $ (1,609 ) $ (1,451 )

Basis of Presentation - Narrati

Basis of Presentation - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Jan. 01, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net cash used in financing activities	$ (7,932)	$ (2,722)
Accounting Standards Update 2016-18
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net cash used in financing activities		$ (100)
Retained Earnings [Member] | Accounting Standards Update 2016-01
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of new accounting principle			$ 17
Accumulated other comprehensive income | Accounting Standards Update 2016-01
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of new accounting principle			$ (17)

Discontinued Operations - Narra

Discontinued Operations - Narrative (Details) - MDSS post-warranty service business - Discontinued operations, disposed of by sale $ in Millions	Feb. 01, 2018USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration received	$ 8
Held in escrow	$ 0.5

Discontinued Operations - Finan

Discontinued Operations - Financial Results (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Operating expenses:
Income from discontinuing operations	$ 5,494	$ 175
MDSS post-warranty service business | Discontinued operations, disposed of by sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total revenues	624	3,240
Total cost of revenues	516	1,735
Gross profit	108	1,505
Operating expenses:
Marketing and sales	85	617
General and administrative	172	208
Amortization of intangible assets	13	204
Gain on sale of discontinued operations	(6,261)	0
Total operating expenses	(5,991)	1,029
Income from discontinued operations	6,099	476
Interest expense	(26)	(122)
Income from discontinuing operations before income taxes	6,073	354
Income tax expense	(579)	(179)
Income from discontinuing operations	$ 5,494	$ 175

Discontinued Operations - Major

Discontinued Operations - Major Classes of Assets and Liabilities Included in Company's Balance Sheet (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Carrying amounts of assets included as part of discontinued operations:
Total assets classified as held for sale in the condensed consolidated balance sheet	$ 0	$ 1,736
Carrying amounts of liabilities included as part of discontinued operations:
Total liabilities classified as held for sale in the condensed consolidated balance sheet	0	835
MDSS post-warranty service business | Discontinued operations, disposed of by sale
Carrying amounts of assets included as part of discontinued operations:
Intangible assets, net	0	637
Goodwill	0	1,099
Total assets classified as held for sale in the condensed consolidated balance sheet	0	1,736
Carrying amounts of liabilities included as part of discontinued operations:
Deferred revenue	0	835
Total liabilities classified as held for sale in the condensed consolidated balance sheet	$ 0	$ 835

Discontinued Operations - Suppl

Discontinued Operations - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of discontinued operations	$ 6,844	$ 0
MDSS post-warranty service business | Discontinued operations, disposed of by sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation	2	9
Amortization of intangible assets	13	204
Gain on sale of discontinued operations	(6,261)	0
Stock-based compensation	(1)	8
Proceeds from sale of discontinued operations	6,844	0
Purchases of property, plant and equipment	$ 0	$ 0

Revenue - Disaggregation of Rev

Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	$ 22,791
Lease Income	2,674
Total revenues	25,465	$ 25,840
Services and goods transferred over time
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	23,175
Services and goods transferred at a point in time
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	2,290
Mobile Imaging and Cardiac Monitoring
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	19,977
Camera
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	1,070
Camera Support
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	1,744
Diagnostic Services
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	11,898
Lease Income	127
Total revenues	12,025	12,202
Diagnostic Services | Services and goods transferred over time
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	10,964
Diagnostic Services | Services and goods transferred at a point in time
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	1,061
Diagnostic Services | Mobile Imaging and Cardiac Monitoring
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	11,898
Diagnostic Services | Camera
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	0
Diagnostic Services | Camera Support
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	0
Diagnostic Imaging
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	2,814
Lease Income	28
Total revenues	2,842	2,783
Diagnostic Imaging | Services and goods transferred over time
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	1,720
Diagnostic Imaging | Services and goods transferred at a point in time
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	1,122
Diagnostic Imaging | Mobile Imaging and Cardiac Monitoring
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	0
Diagnostic Imaging | Camera
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	1,070
Diagnostic Imaging | Camera Support
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	1,744
Mobile Healthcare
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	8,079
Lease Income	2,519
Total revenues	10,598	$ 10,855
Mobile Healthcare | Services and goods transferred over time
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	10,491
Mobile Healthcare | Services and goods transferred at a point in time
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	107
Mobile Healthcare | Mobile Imaging and Cardiac Monitoring
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	8,079
Mobile Healthcare | Camera
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	0
Mobile Healthcare | Camera Support
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	$ 0

Revenue (Details)

Revenue (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Disaggregation of Revenue [Line Items]
Deferred revenue balance	$ 2	$ 2.4
Revenue recognized in period	0.9
Deferred revenue, period increase (decrease)	$ (0.4)
Camera
Disaggregation of Revenue [Line Items]
Warranty term	1 year
Diagnostic Imaging | Camera Support | Minimum
Disaggregation of Revenue [Line Items]
Service contract term	12 months
Diagnostic Imaging | Camera Support | Maximum
Disaggregation of Revenue [Line Items]
Service contract term	48 months

Basic and Diluted Net Income 34

Basic and Diluted Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Numerator:
Loss from continuing operations	$ (1,388)	$ (2,251)
Income from discontinued operations	5,494	175
Net income (loss)	$ 4,106	$ (2,076)
Denominator:
Weighted average shares outstanding – basic (in shares)	20,092	19,933
Dilutive potential common stock outstanding:
Weighted average shares outstanding – diluted	20,092	19,933
Income (loss) per common share - basic
Continuing operations (in usd per share)	$ (0.07)	$ (0.11)
Discontinued operations (in usd per share)	0.27	0.01
Net income (loss) per common share - basic (in usd per share)	0.20	(0.10)
Income (loss) per common share - diluted
Continuing operations (in usd per share)	(0.07)	(0.11)
Discontinued operations (in usd per share)	0.27	0.01
Net income (loss) per common share - diluted (in usd per share)	$ 0.20	$ (0.10)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average outstanding securities excluded from computation of diluted net income (loss) per share (in shares)	336	384
Stock options
Dilutive potential common stock outstanding:
Dilutive potential common stock outstanding (in shares)	0	0
Restricted stock units
Dilutive potential common stock outstanding:
Dilutive potential common stock outstanding (in shares)	0	0
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average outstanding securities excluded from computation of diluted net income (loss) per share (in shares)	207	315
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average outstanding securities excluded from computation of diluted net income (loss) per share (in shares)	129	69

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 2,486	$ 2,331
Work-in-process	1,781	2,094
Finished goods	1,933	1,529
Total inventories	6,200	5,954
Less reserve for excess and obsolete inventories	(445)	(453)
Total inventories, net	$ 5,755	$ 5,501

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property, and equipment, gross	$ 64,484	$ 63,883
Less accumulated depreciation	(37,308)	(35,518)
Total property and equipment, net	27,176	28,365
Land
Property, Plant and Equipment [Line Items]
Property, and equipment, gross	1,170	1,170
Buildings and leasehold improvements
Property, Plant and Equipment [Line Items]
Property, and equipment, gross	2,946	2,946
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, and equipment, gross	55,735	55,152
Computer hardware and software
Property, Plant and Equipment [Line Items]
Property, and equipment, gross	$ 4,633	$ 4,615

Financial Instruments - Financi

Financial Instruments - Financial Assets Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	$ 204	$ 208
Equity securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	204	208
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	116	97
Level 1 | Equity securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	116	97
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	88	111
Level 2 | Equity securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	88	111
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	0	0
Level 3 | Equity securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	$ 0	$ 0

Financial Instruments - Narrati

Financial Instruments - Narrative (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Equity securities
Schedule of Available-for-sale Securities [Line Items]
Equity securities, accumulated unrealized gains	$ 0	$ 17

Financial Instruments - Securit

Financial Instruments - Securities Available for Sale (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, amortized cost basis	$ 221	$ 191
Available-for-sale securities, accumulated unrealized gains	0	17
Available-for-sale securities, accumulated unrealized loss	(17)	0
Fair Value	204	208
Equity securities
Schedule of Available-for-sale Securities [Line Items]
Equity securities, cost	221	191
Equity securities, accumulated unrealized gains	0	17
Equity securities, accumulated unrealized losses	(17)	0
Fair Value	$ 204	$ 208

Debt - Schedule of Debt (Detail

Debt - Schedule of Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Total borrowings	$ 13,001	$ 19,500
Line of Credit | Revolving Credit Facility | Credit Facility Due June 2022
Debt Instrument [Line Items]
Total borrowings	$ 13,001	$ 19,500
Weighted-Average Interest Rate	4.25%	3.90%

Debt - Narrative (Details)

Debt - Narrative (Details)	Jun. 21, 2017USD ($)	Mar. 31, 2018USD ($)	Jan. 30, 2018USD ($)	Dec. 31, 2017USD ($)
Line of Credit Facility [Line Items]
Borrowing outstanding		$ 13,001,000		$ 19,500,000
Line of Credit | Credit Facility Due June 2022 | Revolving Credit Facility
Line of Credit Facility [Line Items]
Borrowing outstanding		$ 13,001,000		$ 19,500,000
Weighted average interest rate		4.25%		3.90%
Fixed charge ratio		1.25
Funded debt to adjusted EBITDA ratio		2.25
Line of Credit | Credit Facility Due June 2022 | Comerica | Revolving Credit Facility
Line of Credit Facility [Line Items]
Debt term	5 years
Maximum borrowing capacity	$ 25,000,000		$ 20,000,000
Letters of credit (not to exceed)	$ 1,000,000
Borrowing availability		$ 6,900,000
Unamortized loan fees, written off		100,000
Unamortized loan fees		$ 200,000
Unused line fee	0.25%
Line of Credit | Credit Facility Due June 2022 | London Interbank Offered Rate (LIBOR) | Comerica | Revolving Credit Facility
Line of Credit Facility [Line Items]
Additional margin rate	2.35%
Basis spread	2.50%
Line of Credit | Credit Facility Due June 2022 | Prime Rate | Comerica | Revolving Credit Facility
Line of Credit Facility [Line Items]
Basis spread	0.50%

Income Tax (Details)

Income Tax (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income from discontinued operations, net of tax	$ 5,494	$ 175
Loss from continuing operations, net of tax	(1,388)	(2,251)
Income tax expense (benefit), continued operations	(455)	607
Unrecognized tax benefits	3,900
Unrecognized tax benefits that would impact effective tax rate	3,500
MDSS post-warranty service business | Discontinued operations, disposed of by sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income from discontinued operations, net of tax	5,494	175
Income tax expense, discontinued operations	579	$ 179
Operating loss carryforward | MDSS post-warranty service business | Discontinued operations, disposed of by sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Operating losses utilized, decrease in deferred tax assets valuation allowance	$ 1,100

Segments (Details)

Segments (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Segment Reporting Information [Line Items]
Condensed consolidated revenue	$ 25,465	$ 25,840
Condensed consolidated gross profit	4,607	5,602
Condensed consolidated income (loss) from operations	(1,609)	(1,451)
Diagnostic Services
Segment Reporting Information [Line Items]
Condensed consolidated revenue	12,025	12,202
Condensed consolidated gross profit	2,247	2,836
Condensed consolidated income (loss) from operations	(290)	16
Diagnostic Imaging
Segment Reporting Information [Line Items]
Condensed consolidated revenue	2,842	2,783
Condensed consolidated gross profit	1,245	1,128
Condensed consolidated income (loss) from operations	(204)	(437)
Mobile Healthcare
Segment Reporting Information [Line Items]
Condensed consolidated revenue	10,598	10,855
Condensed consolidated gross profit	1,115	1,638
Condensed consolidated income (loss) from operations	$ (1,115)	$ (1,030)

Subsequent Events (Details)

Subsequent Events (Details) - $ / shares	May 01, 2018	Mar. 31, 2018	Mar. 31, 2017
Subsequent Event [Line Items]
Dividends declared per common share (in usd per share)		$ 0.055	$ 0.05
Subsequent Event
Subsequent Event [Line Items]
Dividends declared per common share (in usd per share)	$ 0.055